Biogen's (BIIB) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $270.00 target price on the biotechnology company’s stock. Several other research analysts have also recently weighed in on the stock. Truist Financial reiterated a buy rating […]

Related Keywords

Germany ,United States ,Canada ,Erick Rowinsky ,Robertw Baird ,Priya Singhal ,Canaccord Genuity Group ,Nasdaq ,Rise Advisors ,Royal Bank ,Biogen Inc ,Wells Fargo Company ,Biogen Company Profile ,Securities Exchange Commission ,Kb Financial Partners ,Free Report ,Genuity Group ,Moderate Buy ,Stock Down ,Get Free Report ,Exchange Commission ,Director Eric ,Asset Management ,Financial Advisory ,Capital Management ,Biogen Daily ,Biogen ,Nasdaq Biib ,Biib ,Medical ,09062x10 ,Reiterated Rating ,Oppenheimer Holdings Inc ,